Investing.com - Adaptimmune Therapeutics (NASDAQ:ADAP) reported on Monday first quarter earnings that beat analysts' forecasts and revenue that fell short of expectations.
Adaptimmune Therapeutics announced earnings per share of $-0.04 on revenue of $1.4M. Analysts polled by Investing.com anticipated EPS of $-0.2525 on revenue of $4.5M.
Adaptimmune Therapeutics shares are down 51.47% from the beginning of the year, still down 73.47% from its 52 week high of $6.86 set on September 10, 2021. They are under-performing the Nasdaq which is down 17.9% from the start of the year.
Adaptimmune Therapeutics shares gained 7.14% in pre-market trade following the report.
Adaptimmune Therapeutics follows other major Healthcare sector earnings this month
Adaptimmune Therapeutics's report follows an earnings matched by Medtronic on February 22, who reported EPS of $1.37 on revenue of $7.76B, compared to forecasts EPS of $1.37 on revenue of $7.88B.
Zoetis Inc had beat expectations on February 15 with fourth quarter EPS of $1 on revenue of $1.97B, compared to forecast for EPS of $0.9629 on revenue of $1.93B.
Stay up-to-date on all of the upcoming earnings reports by visiting Investing.com's earnings calendar